Targeted Immunotherapy against Distinct Cancer-Associated Fibroblasts Overcomes Treatment Resistance in Refractory HER2+ Breast Tumors

Scientists developed a fully humanized immunocompetent model of HER2+ breast cancer recapitulating ex vivo the biological processes that associated with patients’ response to treatment.